NEWARK, Calif., Nov. 25, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will participate in a fireside chat at the
virtual Piper Sandler 32nd Annual Healthcare Conference taking
place November 30 to December 3,
2020.
The presentation will be available for registered attendees via
the Piper Sandler conference site until December 3, 2020, and will also be available
November 30, 2020, by visiting the
Investors section of the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and other blood disorders. PTG-200
is an orally delivered, gut-restricted, interleukin-23 receptor
specific antagonist peptide in development for the treatment of
inflammatory bowel disease, with Crohn's disease as the initial
indication. In addition to PTG-200, two oral peptide interleukin-23
receptor antagonist candidates from a collaboration with Janssen
Biotech, Inc., are in development and have been selected for
advancement into clinical studies. PN-943 is an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
in development for the treatment of inflammatory bowel disease,
with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-virtual-piper-sandler-32nd-annual-healthcare-conference-301180347.html
SOURCE Protagonist Therapeutics, Inc.